IN-30758

N/A

Report date: 2026/04/08 20:02:35
First In Class

Base Information

Drug NameIN-30758
Drug Alias NameIN30758IN-30758
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTumor-associated antigen modulators
TargetsTumor-associated antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInxMed (Hong Kong) Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesYingshi Biotechnology (Shenzhen) Co LtdInxMed (Hong Kong) Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A